

# Nichola Cooper

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7107139/publications.pdf>

Version: 2024-02-01

87  
papers

3,652  
citations

257450

24  
h-index

144013

57  
g-index

98  
all docs

98  
docs citations

98  
times ranked

3578  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathogenesis, risk factors and therapeutic options for autoimmune haemolytic anaemia in the postâ€transplant setting. <i>British Journal of Haematology</i> , 2022, 196, 45-62.	2.5	7
2	Autocrine vitamin D signaling switches off pro-inflammatory programs of TH1 cells. <i>Nature Immunology</i> , 2022, 23, 62-74.	14.5	105
3	Whole genome sequences discriminate hereditary hemorrhagic telangiectasia phenotypes by non-HHT deleterious DNA variation. <i>Blood Advances</i> , 2022, 6, 3956-3969.	5.2	9
4	Registries in immune thrombocytopenia (ITP) in Europe: the European Research Consortium on ITP (<scp>ERCI</scp>) network. <i>British Journal of Haematology</i> , 2022, 197, 633-638.	2.5	2
5	Iron status influences the response of cord blood megakaryocyte progenitors to eltrombopag in vitro. <i>Blood Advances</i> , 2022, 6, 13-27.	5.2	2
6	A Single-Arm, Long-Term Efficacy and Safety Study of Subcutaneous Romiplostim in Children with Immune Thrombocytopenia. <i>Blood Advances</i> , 2022, , .	5.2	1
7	Immune thrombocytopenia (ITP) World Impact Survey (iWISH): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment. <i>American Journal of Hematology</i> , 2021, 96, 188-198.	4.1	55
8	The under-representation of BAME patients in the COVID-19 Recovery trial at a major London NHS Trust. <i>Journal of Infection</i> , 2021, 82, 84-123.	3.3	9
9	Immune thrombocytopenia (<scp>ITP</scp>) <scp>World Impact Survey</scp> (<scp>iWISH</scp>): Impact of <scp>ITP</scp> on healthâ€related quality of life. <i>American Journal of Hematology</i> , 2021, 96, 199-207.	4.1	54
10	Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110108.	2.5	26
11	Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel. <i>Acta Haematologica</i> , 2021, 144, 418-426.	1.4	17
12	How I treat immune thrombocytopenia â€ a global view. <i>British Journal of Haematology</i> , 2021, 193, 1076-1086.	2.5	4
13	A Review of Romiplostim Mechanism of Action and Clinical Applicability. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 2243-2268.	4.3	35
14	Qualitative study to support the content validity of the immune thrombocytopenia (ITP) Life Quality Index (ILQI). <i>British Journal of Haematology</i> , 2021, 194, 759-766.	2.5	8
15	Definition of a critical bleed in patients with immune thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2082-2088.	3.8	14
16	Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets. <i>Blood</i> , 2021, 138, 1481-1489.	1.4	66
17	Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia. <i>Annals of Hematology</i> , 2021, 100, 2143-2154.	1.8	7
18	Bone marrow remodeling supports hematopoiesis in response to immune thrombocytopenia progression in mice. <i>Blood Advances</i> , 2021, 5, 4877-4889.	5.2	4

#	ARTICLE	IF	CITATIONS
19	Psychometric Evaluation of ITP Life Quality Index (ILQI) in a Global Survey of Patients with Immune Thrombocytopenia. <i>Advances in Therapy</i> , 2021, 38, 5791-5808.	2.9	5
20	Surveillance Program of Romiplostim Use Connected to Pregnancy. <i>Blood</i> , 2021, 138, 585-585.	1.4	2
21	Updated Phase I/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed/Refractory Immune Thrombocytopenia. <i>Blood</i> , 2021, 138, 14-14.	1.4	5
22	How Effective Are the Immunosuppressive Therapies Rituximab and Mycophenolate Mofetil in Immune Thrombocytopenia? Real World Evidence from the UK ITP Registry. <i>Blood</i> , 2021, 138, 1016-1016.	1.4	0
23	Multi-Arm Trial of Inflammatory Signal Inhibitors (MATIS) for Hospitalised Patients with Mild or Moderate COVID-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomised Controlled Trial. <i>Blood</i> , 2021, 138, 4200-4200.	1.4	0
24	LUNA3 Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of the Oral BTK Inhibitor Rilzabrutinib in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia. <i>Blood</i> , 2021, 138, 1010-1010.	1.4	5
25	Immune Thrombocytopenia (ITP): Current Limitations in Patient Management. <i>Medicina (Lithuania)</i> , 2020, 56, 667.	2.0	20
26	Identification of occult cerebral microbleeds in adults with immune thrombocytopenia. <i>Blood</i> , 2020, 136, 2875-2880.	1.4	9
27	Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia. <i>British Journal of Haematology</i> , 2020, 190, 933-938.	2.5	38
28	Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28630.	1.5	6
29	“ITP” is not always immune thrombocytopenia. <i>American Journal of Hematology</i> , 2020, 95, 1614-1615.	4.1	2
30	Whole-genome sequencing of a sporadic primary immunodeficiency cohort. <i>Nature</i> , 2020, 583, 90-95.	27.8	148
31	Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients with Heavily Pretreated Immune Thrombocytopenia. <i>Blood</i> , 2020, 136, 13-14.	1.4	6
32	Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study. <i>Blood</i> , 2020, 136, 1-3.	1.4	4
33	A Multicentre Randomised Trial of First Line Treatment Pathways for Newly Diagnosed Immune Thrombocytopenia: Standard Steroid Treatment Versus Combined Steroid and Mycophenolate. the Flight Trial. <i>Blood</i> , 2020, 136, LBA-2-LBA-2.	1.4	3
34	ITP World Impact Survey (I-WISH) 2.0: Further Exploration of the Impact of ITP on Patients. <i>Blood</i> , 2020, 136, 2-3.	1.4	0
35	A Phase II Study to Assess the Sustained Response Off Treatment in Patients with ITP Receiving Eltrombopag, Who Had a Previous Insufficient Response to Corticosteroids (TAPER): A Recruitment Update. <i>Blood</i> , 2020, 136, 37-38.	1.4	0
36	Mechanisms and therapeutic prospects of thrombopoietin receptor agonists. <i>Seminars in Hematology</i> , 2019, 56, 262-278.	3.4	25

#	ARTICLE	IF	CITATIONS
37	Immune Thrombocytopenia. <i>New England Journal of Medicine</i> , 2019, 381, 945-955.	27.0	238
38	<i>FAS</i> mutations are an uncommon cause of immune thrombocytopenia in children and adults without additional features of immunodeficiency. <i>British Journal of Haematology</i> , 2019, 186, e163-e165.	2.5	6
39	Thrombopoietin receptor agonists: ten years later. <i>Haematologica</i> , 2019, 104, 1112-1123.	3.5	219
40	Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. <i>American Journal of Hematology</i> , 2019, 94, 546-553.	4.1	67
41	Updated international consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood Advances</i> , 2019, 3, 3780-3817.	5.2	593
42	The child with immune thrombocytopenia: to treat or not to treat, is that still the question?. <i>Haematologica</i> , 2019, 104, 2132-2134.	3.5	1
43	American Society of Hematology 2019 guidelines for immune thrombocytopenia. <i>Blood Advances</i> , 2019, 3, 3829-3866.	5.2	684
44	Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia. <i>Blood</i> , 2019, 134, 87-87.	1.4	12
45	Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) Patients. <i>Blood</i> , 2019, 134, 1069-1069.	1.4	2
46	Updated Results from the Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP). <i>Blood</i> , 2019, 134, 1095-1095.	1.4	6
47	Eltrombopag: More Than Just a Thrombopoietin Receptor Agonist (TPO-RA) in Immune Thrombocytopenia (ITP). <i>Blood</i> , 2019, 134, 2364-2364.	1.4	1
48	The Psychometric Properties of the ITP Life Quality Index Assessed in a Large Multinational "Real-World" Cohort of Immune Thrombocytopaenia Patients. <i>Blood</i> , 2019, 134, 386-386.	1.4	3
49	Dose-Dependent Iron Chelating Effects of Eltrombopag on in Vitro Human Megakaryopoiesis. <i>Blood</i> , 2019, 134, 2475-2475.	1.4	0
50	Physicians' and Patients' Perspectives on Treatments in ITP - a Multi-Country Perspective: Results from the ITP World Impact Survey (I-WISH). <i>Blood</i> , 2019, 134, 1097-1097.	1.4	1
51	Trial in Progress: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Global Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia. <i>Blood</i> , 2019, 134, 4800-4800.	1.4	0
52	Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. <i>American Journal of Hematology</i> , 2018, 93, 921-930.	4.1	215
53	A United Kingdom Immune Thrombocytopenia (<sc>ITP</sc>) Forum review of practice: thrombopoietin receptor agonists. <i>British Journal of Haematology</i> , 2018, 180, 591-594.	2.5	7
54	Human retinoic acid-regulated CD161+ regulatory T cells support wound repair in intestinal mucosa. <i>Nature Immunology</i> , 2018, 19, 1403-1414.	14.5	86

#	ARTICLE	IF	CITATIONS
55	Trial protocol: a multicentre randomised trial of first-line treatment pathways for newly diagnosed immune thrombocytopenia: standard steroid treatment versus combined steroid and mycophenolate. The FLIGHT trial. <i>BMJ Open</i> , 2018, 8, e024427.	1.9	20
56	Evidence-based management of immune thrombocytopenia: ASH guideline update. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 568-575.	2.5	60
57	Patients with Immune Thrombocytopenia (ITP) Frequently Experience Severe Fatigue but Is It Under-Recognized By Physicians: Results from the ITP World Impact Survey (I-WISH). <i>Blood</i> , 2018, 132, 2273-2273.	1.4	14
58	Results from the ITP World IMPACT Survey (I-WISH): Patients with Immune Thrombocytopenia (ITP) Experience Impaired Quality of Life (QoL) Regarding Daily Activities, Social Interactions, Emotional Well-Being and Working Lives. <i>Blood</i> , 2018, 132, 4804-4804.	1.4	4
59	Active Immune Thrombocytopenia (ITP) Disease Is Characterised By a Reduced Treg:CD8 Effector T Cell Ratio Which Is Modulated By Thrombopoietin-Receptor Agonists (TPO-RA). <i>Blood</i> , 2018, 132, 2430-2430.	1.4	1
60	State of the art " how I manage immune thrombocytopenia. <i>British Journal of Haematology</i> , 2017, 177, 39-54.	2.5	98
61	BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency. <i>Nature Immunology</i> , 2017, 18, 813-823.	14.5	113
62	Haematology in Lower and Middle Income Countries. <i>British Journal of Haematology</i> , 2017, 177, 833-835.	2.5	3
63	Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator. <i>Blood</i> , 2017, 130, 1923-1933.	1.4	98
64	Immune thrombocytopenia: a need for assisted suicide. <i>British Journal of Haematology</i> , 2017, 176, 154-154.	2.5	1
65	Emperipoleis in a patient receiving romiplostim. <i>American Journal of Hematology</i> , 2016, 91, 166-166.	4.1	2
66	Eltrombopag (ELT) Reverses Iron Mediated Suppression of Insulin Secretion in Pancreatic Cells By Chelating Iron and Decreasing ROS. <i>Blood</i> , 2016, 128, 1278-1278.	1.4	2
67	A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP). <i>Blood</i> , 2016, 128, 869-869.	1.4	3
68	Cytokine Fluctuations in Immune Thrombocytopenia (ITP) over Time; Insights into the Pathogenesis and Evolution of the Disease. <i>Blood</i> , 2016, 128, 2549-2549.	1.4	3
69	Natural Killer Cells Improve Hematopoietic Stem Cell Engraftment by Increasing Stem Cell Clonogenicity In Vitro and in a Humanized Mouse Model. <i>PLoS ONE</i> , 2015, 10, e0138623.	2.5	11
70	Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥65 years with immune thrombocytopenia. <i>Annals of Hematology</i> , 2015, 94, 1973-1980.	1.8	25
71	A Potential Novel Application of Eltrombopag: A Combination Agent to Enhance Iron Chelation Therapy. <i>Blood</i> , 2015, 126, 3357-3357.	1.4	2
72	The coming of age of the megakaryocyte-platelet. <i>British Journal of Haematology</i> , 2014, 165, 161-162.	2.5	0

#	ARTICLE	IF	CITATIONS
73	Differential effects of mycophenolate mofetil and cyclosporine A on peripheral blood and cord blood natural killer cells activated with interleukin-2. <i>Cytotherapy</i> , 2014, 16, 1409-1418.	0.7	21
74	A review of the management of childhood immune thrombocytopenia: how can we provide an evidence-based approach?. <i>British Journal of Haematology</i> , 2014, 165, 756-767.	2.5	36
75	Eltrombopag Mobilizes Intracellular Iron Stores at Concentrations Lower Than Those Required with Other Clinically Available Iron Chelators. <i>Blood</i> , 2014, 124, 1353-1353.	1.4	6
76	CD161 Expression Identifies a Distinct Subset Of Drug-Effluxing Viral-Specific Memory CD4+ T Cells That Preferentially Survive Cytotoxic Chemotherapy. <i>Blood</i> , 2013, 122, 2024-2024.	1.4	0
77	Alternative Methods Of Thrombocytopenia: Patients With ITP Have Increased Megakaryocyte/T Cell Interactions In The Bone Marrow and Higher Serum TRAIL Levels. <i>Blood</i> , 2013, 122, 3531-3531.	1.4	0
78	The Influence Of KIR Haplotype In ITP Incidence, Treatment Response and Bleeding Symptoms. <i>Blood</i> , 2013, 122, 2316-2316.	1.4	0
79	The efficacy and safety of romiplostim in adult patients with chronic immune thrombocytopenia. <i>Therapeutic Advances in Hematology</i> , 2012, 3, 291-298.	2.5	16
80	Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia. <i>British Journal of Haematology</i> , 2012, 158, 539-547.	2.5	39
81	Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP). <i>Blood</i> , 2012, 120, 1096-1096.	1.4	5
82	Rate of Cataracts Across the Eltrombopag Clinical Studies in Patients with Chronic Immune Thrombocytopenia. <i>Blood</i> , 2011, 118, 1164-1164.	1.4	6
83	The Long-term Impact of Rituximab for Childhood Immune Thrombocytopenia. <i>Current Rheumatology Reports</i> , 2010, 12, 94-100.	4.7	26
84	The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. <i>British Journal of Haematology</i> , 2010, 149, 3-13.	2.5	134
85	KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib. <i>Blood</i> , 2010, 116, 888-888.	1.4	0
86	Intravenous Immunoglobulin and Anti-RhD Therapy in the Management of Immune Thrombocytopenia. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 1317-1327.	2.2	35
87	Lymphocyte Homeostasis FAS Pathway Is Altered in Some Patients with Immune Thrombocytopenia.. <i>Blood</i> , 2009, 114, 3514-3514.	1.4	0